Breaking News Instant updates and real-time market news.

PBYI

Puma Biotechnology

$38.05

1.35 (3.68%)

16:21
03/01/17
03/01
16:21
03/01/17
16:21

Puma Biotechnology reports Q4 adjusted EPS ($1.22), consensus ($1.92)

Reports Q4 R&D expenses $56.4M vs $52.5M last year. "We made significant progress with the neratinib clinical program during the fourth quarter," said Alan H. Auerbach, Chairman, Chief Executive Officer and President of Puma. "We presented additional results of several ongoing studies at the 2016 San Antonio Breast Cancer Symposium, including our Phase II CONTROL trial of PB272 in the extended adjuvant treatment of HER2-positive early stage breast cancer; a biomarker analysis of the NSABP FB-7 Phase II trial for the neoadjuvant treatment of HER2-positive locally advanced breast cancer; and the Phase II SUMMIT trial of PB272 for ERBB2 mutant, HER2 non-amplified metastatic breast cancer. We also initiated a Managed Access Program for PB272 outside the United States, providing physicians and patients access to PB272 when there are limited or no other therapeutic options available."

  • 21

    Jul

PBYI Puma Biotechnology
$38.05

1.35 (3.68%)

11/14/16
JPMS
11/14/16
NO CHANGE
JPMS
Puma Biotechnology selloff today an overreaction, says JPMorgan
JPMorgan analyst Cory Kasimov views the selloff today in shares of Puma Biotechnology as an overreaction. The diarrhea rates included in abstract posted today are worse than the last update, but the rates are equivalent to a median number of around 1 episode per patient in the first cycle of treatment, Kasimov tells investors in an intraday research note. He continues to consider neratinib an approvable drug based on currently available data.
11/14/16
STFL
11/14/16
NO CHANGE
Target $88
STFL
Buy
Stifel calls Puma selloff overdone, but concerned by management comments
Stifel analyst Thomas Shrader views the intraday selloff in Puma Biotechnology shares as an overreaction, but he calls management's comments last week "an issue." At a conference last week, management said, "In December, we showed the interim results of this and as you can see the grade 3 diarrhea ranged from 13% to 18%. And also, all of the things that would be involved in tolerability, like stopping the drug, reducing the drug, or discontinuing were all brought down as well. Here, you can see the diarrhea over time in the control study." Shrader believes today's abstract was likely embargoed, but he still finds last week's comments "strange." Nonetheless, the analyst feels neratinib's Grade 3 diarrhea rate is manageable and he notes that Grade 4 diarrhea events were zero in all arms of the trial. Shrader has a Buy rating on Puma with an $88 price target.
01/03/17
SBSH
01/03/17
NO CHANGE
Target $88
SBSH
Buy
Citi finds 'bullish' Youtube videos for Puma cancer drug
Two new "Key Opinion Leader" videos expressing continued optimism on Puma Biotechnology's breast cancer drug neratinib posted on Youtube within the last several weeks, Citi analyst Yigal Nochomovitz tells investors in a research note. Similar to two videos posted in August, the new videos have received very little online attention with 25-30 views, the analyst contends. Nochomovitz believes Key Opinion Leader interest in neratinib continues to accelerate. The analyst notes a doctor in one of the videos said the chances of getting "significant diarrhea go way, way down" after a month. He keeps a Buy rating on Puma shares with an $88 price target. The stock closed Friday up 15c to $30.70.
02/01/17
SBSH
02/01/17
NO CHANGE
Target $88
SBSH
Buy
Citi sees Puma doubling if Roche study is negative
Citi analyst Yigal Nochomovitz believes shares of Puma Biotechnology (PBYI) could rally 100% or more if Roche (RHHBY) reports a negative Phase III Aphinity study readout of Perjeta in the adjuvant treatment of HER2-positive early breast cancer. The analyst, which notes Roche slides today point to a data readout in late February or early March, sees maximum downside for Puma shares of 30% should Aphinity succeed. A selloff would be a "very good opportunity to buy the dip" as despite the controversy around neratinib's benefit/risk profile, neratinib should be approved by the FDA for extended adjuvant, Nochomovitz tells investors in a research note. The FDA action date for neratinib is in July. The analyst adds that recent stock sales by Puma management were in the context of tax obligations required for vesting of restricted stock units. Management's net ownership in the company has actually increased with the vesting of a tranche of restricted stock, Nochomovitz writes. He has a Buy rating on Puma with an $88 price target. The stock is unchanged at $32.40 in morning trading.

TODAY'S FREE FLY STORIES

WLL

Whiting Petroleum

$5.13

-0.135 (-2.57%)

12:45
10/17/17
10/17
12:45
10/17/17
12:45
Options
Whiting Petroleum call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

MAR

Marriott

$114.75

-0.36 (-0.31%)

12:39
10/17/17
10/17
12:39
10/17/17
12:39
Hot Stocks
Marriott says Ed Ryan to retire as general counsel »

Marriott International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

  • 30

    Nov

VSTM

Verastem

$4.21

-0.14 (-3.22%)

12:35
10/17/17
10/17
12:35
10/17/17
12:35
Conference/Events
Verastem management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

VALE

Vale

$10.28

-0.225 (-2.14%)

12:34
10/17/17
10/17
12:34
10/17/17
12:34
Periodicals
Vale seeks partner to invest in New Caledonia mine, FT reports »

Vale is seeking a partner…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SB

Safe Bulkers

$3.21

-0.03 (-0.93%)

12:33
10/17/17
10/17
12:33
10/17/17
12:33
Conference/Events
Safe Bulkers management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 18

    Oct

  • 19

    Oct

CREE

Cree

$29.28

-0.08 (-0.27%)

12:29
10/17/17
10/17
12:29
10/17/17
12:29
Technical Analysis
Technical Earnings Preview: Cree near top of range ahead of results »

The shares were trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

PYPL

PayPal

$67.31

-1.35 (-1.97%)

12:25
10/17/17
10/17
12:25
10/17/17
12:25
Recommendations
PayPal analyst commentary  »

PayPal price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 18

    Oct

  • 19

    Oct

  • 19

    Oct

  • 22

    Oct

  • 29

    Nov

LNG

Cheniere Energy

$48.20

0.48 (1.01%)

12:25
10/17/17
10/17
12:25
10/17/17
12:25
Options
Cheniere Energy call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:25
10/17/17
10/17
12:25
10/17/17
12:25
General news
U.S. corporate bond update: the calendar is relatively slim »

U.S. corporate bond…

CYTR

CytRx

$0.38

-0.0142 (-3.64%)

12:25
10/17/17
10/17
12:25
10/17/17
12:25
Conference/Events
CytRx to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

12:25
10/17/17
10/17
12:25
10/17/17
12:25
Conference/Events
Federal Reserve Bank of Philadelphia President speaks at summit »

Federal Reserve Bank of…

12:25
10/17/17
10/17
12:25
10/17/17
12:25
Conference/Events
American Association for Cancer Research holds a webinar »

Webinar entitled,…

GOOG

Alphabet

$992.00

2.32 (0.23%)

12:20
10/17/17
10/17
12:20
10/17/17
12:20
Hot Stocks
Google refreshes Google Calendar for web »

Google said in a post to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 24

    Oct

  • 26

    Oct

  • 29

    Nov

JNJ

Johnson & Johnson

$139.15

3.03 (2.23%)

12:20
10/17/17
10/17
12:20
10/17/17
12:20
Periodicals
Appeals court throws out $72M verdict against J&J, St. Louis Post-Dispatch says »

The appeals court of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 23

    Oct

  • 27

    Oct

  • 06

    Nov

12:20
10/17/17
10/17
12:20
10/17/17
12:20
General news
Treasury's $40 B 4-week bill garnered solid results »

Treasury's $40 B…

SPX

S&P 500

12:19
10/17/17
10/17
12:19
10/17/17
12:19
Hot Stocks
Trump expected to pick Fed chair before Asia trip, CNBC reports »

President Trump is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

12:17
10/17/17
10/17
12:17
10/17/17
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

12:16
10/17/17
10/17
12:16
10/17/17
12:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNAP

Snap

$16.21

0.135 (0.84%)

12:15
10/17/17
10/17
12:15
10/17/17
12:15
Periodicals
Snap says advertising will stay main source of revenue, Bloomberg says »

Snap's head of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 07

    Nov

HBI

Hanesbrands

$23.28

-0.11 (-0.47%)

12:15
10/17/17
10/17
12:15
10/17/17
12:15
Options
HanesBrands put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:15
10/17/17
10/17
12:15
10/17/17
12:15
General news
U.S. equities have been waffling »

U.S. equities have been…

BC

Brunswick

$57.82

0.2324 (0.40%)

12:14
10/17/17
10/17
12:14
10/17/17
12:14
Hot Stocks
Brunswick raises quarterly dividend 15% to 19c per share »

The board of directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 26

    Oct

SNAP

Snap

$16.23

0.155 (0.96%)

12:11
10/17/17
10/17
12:11
10/17/17
12:11
Periodicals
Snap to broaden program types, partnerships with TV companies, Bloomberg says »

Snap to invest in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 07

    Nov

12:10
10/17/17
10/17
12:10
10/17/17
12:10
General news
FX Action: USD-JPY »

FX Action: USD-JPY has…

SSNLF

Samsung

, AAPL

Apple

$159.88

2.89 (1.84%)

12:07
10/17/17
10/17
12:07
10/17/17
12:07
Periodicals
Samsung's Galaxy S8 tops consumer review performance list, Yonhap News reports »

The Samsung (SSNLF)…

SSNLF

Samsung

AAPL

Apple

$159.88

2.89 (1.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 30

    Oct

  • 02

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.